News | March 04, 2024
Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
Launch of Indian public health standards for Ayush healthcare facilities
Launch of Indian public health standards for Ayush healthcare facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cipla completes transfer of Generics Business Undertaking
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
